Table 1.
Summary of variables
| Variable group | Variable description | Distribution used in PSA | Mean value | Source |
|---|---|---|---|---|
| Model settings | Age of patients entering the model | 70 | ||
| Model time horizon | 10 | |||
| Costs | Cost of an implant complication | Fixed | £1090 | UK reference costs |
| Total cost of implant procedure including cost of equipment and device | Fixed | £12 000 | Estimate | |
| Monthly cost to deliver medical care | fixed | £36 | Griffiths et al. 17 | |
| Cost of a HF hospitalization | normal | £2038 | UK reference costs | |
| Hourly rate for Band 5 nurse | Not run in base case Sensitivity analysis only | £36 | PSSRU21 | |
| Hazard ratio | Hazard ratio reduction in HF hospitalization treatment cohort | Log normal | 0.67 | Abraham et al. 37 |
| Hazard ratio reduction in mortality treatment cohort | Log normal | 0.8 | Abraham et al. 37 | |
| Risk of implant complication | Fixed | 0.0272 | CHAMPION trial data | |
| Risks | Monthly risk of HF hospitalization | Beta | 0.035 | Klersy et al. 16 |
| Mortality risk age 45–50 | Beta | 0.00125 | Griffiths et al. 17 | |
| Age‐related mortality risk | Mortality risk age 50–55 | Beta | 0.00197 | Griffiths et al. 17 |
| Mortality risk age 55–60 | Beta | 0.00296 | Griffiths et al. 17 | |
| Mortality risk age 60–65 | Beta | 0.0046 | Griffiths et al. 17 | |
| Mortality risk age 65–70 | Beta | 0.00698 | Griffiths et al. 17 | |
| Mortality risk age 70–75 | Beta | 0.01044 | Griffiths et al. 17 | |
| Mortality risk age 75–80 | Beta | 0.01566 | Griffiths et al. 17 | |
| Mortality risk age 80–85 | Beta | 0.02136 | Griffiths et al. 17 | |
| Mortality risk age 85–90 | Beta | 0.02301 | Griffiths et al. 17 | |
| Mortality risk age 90+ | Beta | 0.01864 | Griffiths et al. 17 | |
| Utility values for CardioMEMS patients | Trial utility at 1 month for treatment group | Normal | 0.688 | CHAMPION trial data |
| Trial utility at 3 months for treatment group | Normal | 0.646 | CHAMPION trial data | |
| Trial utility at 6 months for treatment group | Normal | 0.617 | CHAMPION trial data | |
| Trial utility at 12 months for treatment group | Normal | 0.653 | CHAMPION trial data | |
| Utility values for usual care patients | Trial utility at 1 month for usual care | Normal | 0.645 | CHAMPION trial data |
| Trial utility at 3 months for usual care | Normal | 0.569 | CHAMPION trial data | |
| Trial utility at 6 months for usual care | Normal | 0.566 | CHAMPION trial data | |
| Trial utility at 12 months for usual care | Normal | 0.547 | CHAMPION trial data | |
| Utility value for stable HF patients | Utility for patients with chronic HF | Fixed | 0.57 | Matza et al. 19 |
| Disutility for hospitalization | Disutility for HF hospitalization after 5 years | Triangular | −0.1 | Klersy et al. 16 |
HF, heart failure; PSA, probabilistic sensitivity analysis; PSSRU, Personal Social Services Research Unit.